AstraZeneca's immunotherapy drug scores key Phase III lung cancer win - MedCity News

AstraZeneca's immunotherapy drug scores key Phase III lung cancer win  MedCity News

The company said the Phase III CASPIAN study of Imfinzi in first-line, extensive-stage small-cell lung cancer was successful, but did not disclose further details.



Comments

Popular posts from this blog

Lymph node metastasis in cancer progression: molecular mechanisms, clinical significance and therapeutic ...

Stage 4 Lung Cancer Life Expectancy

A Review of the Etiology and Epidemiology of Bladder Cancer: All ...